Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sequencing capacity ramp-ups, antibody pipeline milestones, and cash-burn assumptions make Twist Bioscience鈥檚 SEC disclosures uniquely complex. Locating gene-synthesis revenue mix in the Twist Bioscience annual report 10-K simplified filing or tracing collaboration updates buried in an 8-K often means scrolling through hundreds of pages. Stock Titan solves this pain point by turning dense biotechnology jargon into concise insights, giving you twist bioscience SEC filings explained simply without losing critical detail.
Our AI reads every document the instant it hits EDGAR, delivering Twist Bioscience Form 4 insider transactions real-time, red-flagging risk-factor changes, and extracting segment metrics into dashboards. Whether you鈥檙e searching for a twist bioscience quarterly earnings report 10-Q filing, a sudden twist bioscience 8-K material events explained, or the latest twist bioscience proxy statement executive compensation tables, the platform highlights exactly where the numbers live and what they mean. Smart tags link cash-flow shifts to R&D spending so you can perform twist bioscience earnings report filing analysis in minutes, not hours.
Need to monitor management moves before the next capital raise? Track every twist bioscience insider trading Form 4 transactions alert or dive deeper into twist bioscience executive stock transactions Form 4 to spot buying trends. From cost-of-goods disclosures that impact gross margin to litigation notes that could reshape IP value, our expert commentary keeps you ahead. If you鈥檙e focused on understanding Twist Bioscience SEC documents with AI, start here鈥攃omprehensive coverage, real-time updates, and plain-English explanations for every filing type.
Twist Bioscience (TWST) filed a Form 144 disclosing a proposed sale of 619 common shares with an aggregate market value of $16,071.84, to be sold approximately on 08/21/2025 on NASDAQ. The shares were acquired on 08/20/2025 upon restricted stock vesting and were issued as compensation. The filer reports prior sales by the same person, Paula Green, totaling 3,174 shares across five transactions between 05/21/2025 and 08/04/2025, producing gross proceeds of $97,059.51. The filer certifies they are unaware of any undisclosed material adverse information about the issuer.
Twist Bioscience (TWST) Form 144 notice: An insider proposes to sell 918 shares of common stock through Fidelity Brokerage Services on 08/21/2025, with an aggregate market value of $23,835.14. The shares were acquired by restricted stock vesting on 08/20/2025 and are being sold as compensation. The issuer has 60,360,925 shares outstanding, making this proposed sale a very small portion of the outstanding shares. The filing also discloses prior insider sales by Adam Laponis of 936 shares on 05/21/2025 (gross proceeds $27,843.57) and 2,449 shares on 07/09/2025 (gross proceeds $93,419.31). The notice includes the standard insider certification that no undisclosed material adverse information is known to the seller.
Form 144 notice from Twist Bioscience (TWST) shows an insider sale filing for common stock. The filer plans to sell 238 shares via Fidelity Brokerage Services on NASDAQ with an aggregate market value of $6,179.48 and an approximate sale date of 08/21/2025. The shares were acquired on 08/20/2025 through restricted stock vesting and were received as compensation. The filing lists four prior small common-stock sales by Robert Werner totaling 1,492 shares between 05/21/2025 and 08/04/2025 with gross proceeds reported for each sale. The notice includes the standard certification that the signer is unaware of undisclosed material adverse information.
Twist Bioscience (TWST) insider sale notice: This Form 144 reports a proposed sale of 521 common shares by an insider through Fidelity Brokerage Services with an aggregate market value of $13,527.35. The company has 60,360,925 shares outstanding and the sale is planned for 08/21/2025 on NASDAQ.
The shares were acquired on 08/20/2025 by restricted stock vesting as compensation and became payable on the same date. The filer previously sold common shares in six transactions between 05/21/2025 and 08/04/2025, totaling 2,022 shares for gross proceeds of $60,115.91. The filer certifies no undisclosed material adverse information.
Artisan Partners and several affiliated entities report beneficial ownership of 5,061,033 shares of Twist Bioscience common stock, equal to 8.4% of the outstanding class based on 59,916,141 shares outstanding as of 05/01/2025. The filing shows shared voting power of 4,078,039 shares and no sole voting or dispositive power reported.
The shares were acquired for and are held on behalf of discretionary clients of Artisan Partners Limited Partnership. The filing includes a certification that the holdings are held in the ordinary course of business and were not acquired to change or influence control of the issuer. No other person is reported to have an economic interest above 5% in these shares.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
